Explore more publications!

Health Wire East Timor: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Wire East Timor.

Press releases published on November 7, 2025

Maximus Announces First-Ever Topical Oxytocin Cream for Mood Enhancement and Sleep Support
All Smiles Dental Studio Launches Full Dental Implant Services and In-House Membership Plan to Support the Encinitas Community
Protext Mobility, Inc. (OTC: TXTM) Announces Launch Phase of Its Next-Generation Investor Relations Suite and Corporate Website Modernization — Ushering in a New Era of Transparency, Innovation, and Shareholder Confidence
PetVivo Sets Fiscal Second Quarter 2026 Conference Call for Friday, November 14, 2025 at 5:00 p.m. ET
Neurocept Unveiled: Exploring the Science Behind This Neurocept Brain Support Supplement Transforms Cognitive Health and Memory Enhancement
Global Patient Monitoring Market to Reach $55.8 Billion by End of 2030
Présentation poster sur OSE-Cytomask®, une technologie innovante de « Cis-Démasquage » des cytokines visant à augmenter l’indice thérapeutique des immunocytokines
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines
Chemed Corporation Declares Quarterly Dividend of 60 Cents
ADARx Pharmaceuticals Announces Positive Interim Phase 1 Clinical Data for its Novel siRNA Targeting Complement Factor B (CFB)
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
Upcoming Knock Out Opioid Abuse Day  Webinar to Focus on the Biology of Addiction
Easy Environmental Solutions Begins Trading Under New Ticker Symbol “EZES”
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer Interception in Lynch Syndrome Carriers
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
Trained Therapeutix Demonstrates RIDE-001 Trains Myeloid Cells for Anti-Tumor Immune Response in Preclinical Data Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions